Dual-Targeting Radiopharmaceutical Therapy Demonstrates Safety and Effectiveness in Treating Multiple Cancers

A groundbreaking cancer treatment utilizing dual-targeting radiopharmaceuticals has shown promising results in both safety and effectiveness across various cancer types. This innovative approach works like a 'smart missile,' attaching to two specific markers on cancer cells simultaneously to deliver targeted radiation exactly where it's needed. Early clinical trials reveal that nearly 90% of patients experienced either tumor reduction or disease stabilization. These encouraging findings were presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting.

The therapy involves a novel radiolabeled compound, ¹⁷⁷Lu-DOTA-FAPI-RGD, which targets two tumor-associated markers—fibroblast activation protein (FAP) and integrin αvβ3—enhancing tumor uptake and therapeutic response. In a first-in-human study, nine patients with advanced adenocarcinomas, including pancreatic, lung, renal, and ovarian cancers, received a single treatment cycle. Imaging with ⁶⁸Ga-FAPI-RGD PET/CT confirmed tumor uptake prior to treatment, and safety assessments showed no significant side effects.

The treatment's efficacy was evident through post-treatment imaging, showing substantial tumor shrinkage and, in many cases, disappearance of lung metastases. Patients reported symptomatic relief, including less pain and improved appetite, alongside overall better quality of life. The therapy’s prolonged tumor retention allows for sustained damage to cancer cells without significant toxicity, making it a promising option for patients with limited treatment alternatives.

Jialing Xiang, a Ph.D. student involved in the research, highlighted the potential of this approach, emphasizing its ability to deliver high doses of radiation directly to tumors while sparing healthy tissue. Future trials are planned to optimize dosing and expand understanding of long-term benefits, marking a significant advance in targeted cancer therapy.

This dual-targeting strategy signifies an important step forward in nuclear medicine, offering hope for more effective treatments that are safe and well-tolerated across a broad spectrum of cancers.